Live
- First Impressions and Unboxing of the MacBook Pro M4: A Powerhouse for Professionals and Creators
- China Gears Up for Potential Trade War Amid Trump’s Tariff Threats
- Small Farmers Gain Less by Selling to Supermarkets: Study Reveals
- Why Despite the Controversy, America Is Anticipating the Mike Tyson vs. Jake Paul Fight
- Sanju Samson and Tilak Varma Shine: Record-Breaking Feats in 4th T20I Against South Africa
- India Urges $1.3 Trillion Annual Climate Support for Developing Nations
- Bad air: 106 shuttle buses, 60 extra Metro trips planned to make Delhiites give up cars
- WHO reports declining monkeypox cases in Congo
- CM Attends Kotideepotsavam on Kartika Purnima
- PKL Season 11: Raiding trio of Devank, Ayan, Sandeep help Patna Pirates rout Bengal Warriorz
Dr Reddy’s FDA gets nod for psoriasis drug Impoyz
Dr Reddy’s Laboratories (DRL) has received first cycle new drug application (NDA) approval from the US Food and Drug Administration (USFDA) for its psoriasis treatment Impoyz cream.
Hyderabad: Dr Reddy’s Laboratories (DRL) has received first cycle new drug application (NDA) approval from the US Food and Drug Administration (USFDA) for its psoriasis treatment Impoyz cream. Dr Reddy's Laboratories in a release said that “Through its wholly-owned subsidiary Promius Pharma LLC, it has received its fifth consecutive, first-cycle NDA approval from the US health regulator for the Proprietary Products Group.”
“We’re looking forward to working with our partner, Encore Dermatology, to bring this novel treatment to providers and their patients,” Promius Pharma President and Senior Vice President, Proprietary Products Anil Namboodiripad said.
Robert Moccia, CEO of Encore Dermatology Inc, said: “Encore is excited about adding another great product to our portfolio and looking forward to the opportunity to commercialise a new product for the treatment of mild to moderate psoriasis as well as broadening our portfolio outside of atopic dermatitis and acne.” Impoyz, formerly referred to as DFD-06, had been recently licensed to Encore Dermatology Inc for the commercialisation of the product in the US.
